Literature DB >> 9561947

Current management of infectious complications in the injecting drug user.

C Contoreggi1, V E Rexroad, W R Lange.   

Abstract

The diagnosis and management of infectious complications associated with injection drug use (IDU) are among some of the more challenging aspects of working with substance abusing populations. As the population of injection drug users age, we expect the number and severity of these complications to increase. Commonly seen infections, such as bacterial endocarditis and bacterial infections of bones, joints, and soft tissue, are now frequently complicated by concurrent immunodeficiency. Parenterally and sexually transmitted viral hepatitis is responsible for significant IDU morbidity and mortality. The human leukemia/lymphoma virus types I and II are increasing in prevalence in the IDU with uncertain long-term clinical effects. Immune dysfunction has been described in the IDU for decades, but the impact of host immune compromise on the transmission and the course of HIV-1 has yet to be fully appreciated. The integration of the treatment of substance abuse and its concurrent psychiatric disorders with the management of infectious complications, including immunodeficiency, promises to improve patient compliance with possible savings of overall medical costs.

Entities:  

Mesh:

Year:  1998        PMID: 9561947     DOI: 10.1016/s0740-5472(97)00048-2

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  12 in total

1.  HIV transmission and the cost-effectiveness of methadone maintenance.

Authors:  G S Zaric; P G Barnett; M L Brandeau
Journal:  Am J Public Health       Date:  2000-07       Impact factor: 9.308

2.  Case-reporting of acute hepatitis B and C among injection drug users.

Authors:  Holly Hagan; Nadine Snyder; Eileen Hough; Tianji Yu; Shelly McKeirnan; Janice Boase; Jeffrey Duchin
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

3.  A vulnerable population in a time of crisis: drug users and the attacks on the World Trade Center.

Authors:  Linda Weiss; Antonella Fabri; Kate McCoy; Phillip Coffin; Julie Netherland; Ruth Finkelstein
Journal:  J Urban Health       Date:  2002-09       Impact factor: 3.671

Review 4.  Drug interactions between antiretroviral medications and medications used in the treatment of drug addiction: research needs.

Authors:  Jag H Khalsa; Ahmed Elkashef
Journal:  Am J Addict       Date:  2010 Jan-Feb

Review 5.  Medical consequences of drug abuse and co-occurring infections: research at the National Institute on Drug Abuse.

Authors:  Jag H Khalsa; Glenn Treisman; Elinore McCance-Katz; Ellen Tedaldi
Journal:  Subst Abus       Date:  2008       Impact factor: 3.716

6.  Understanding prolonged cessation from heroin use: findings from a community-based sample.

Authors:  Linda Weiss; Jonathon Gass; James E Egan; Danielle C Ompad; Claudia Trezza; David Vlahov
Journal:  J Psychoactive Drugs       Date:  2014 Apr-Jun

7.  Assessment and Management of Endocarditis Among People Who Inject Drugs in the General Hospital Setting.

Authors:  Joji Suzuki
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-04-10

8.  Exploring drug users' attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S.

Authors:  Corrine E Munoz-Plaza; Shiela Strauss; Janetta Astone-Twerell; Don Des Jarlais; Marya Gwadz; Holly Hagan; Andrew Osborne; Andrew Rosenblum
Journal:  Int J Drug Policy       Date:  2007-08-06

9.  Environmental conditions, political economy, and rates of injection drug use in large US metropolitan areas 1992-2002.

Authors:  Eric T Roberts; Samuel R Friedman; Joanne E Brady; Enrique R Pouget; Barbara Tempalski; Sandro Galea
Journal:  Drug Alcohol Depend       Date:  2009-09-12       Impact factor: 4.492

10.  The content and comprehensiveness of hepatitis C education in methadone maintenance and drug-free treatment units.

Authors:  Shiela M Strauss; Janetta M Astone; Holly Hagan; Don C Des Jarlais
Journal:  J Urban Health       Date:  2004-03       Impact factor: 3.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.